The stress kinase p38α as a target for cancer therapy

Cancer Research

Volumn 75, Issue 19, 2015, Pages 3997-4002

  Igea, Ana ^a   Nebreda, Angel R ^a,b  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^b INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; IMATINIB; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE 14; RITUXIMAB; SORAFENIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER THERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; COLON CANCER; DORMANCY; DOWN REGULATION; DRUG TARGETING; ENZYME INHIBITION; HUMAN; LIVER CANCER; LUNG CANCER; METASTASIS; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL TRANSFORMATION; COLON; DRUG EFFECTS; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYMOLOGY; LIVER; LUNG; MOLECULARLY TARGETED THERAPY; MOUSE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL TRANSFORMATION, NEOPLASTIC; COLON; DRUG SYNERGISM; ENZYME ACTIVATION; HUMANS; LIVER; LUNG; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 14; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84945534999     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0173     Document Type: Review

References (35)

1. Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J 2010;429:403-17.
2. Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 2007;1773:1358-75.
3. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009;9:537-49.
4. Bulavin DV, Fornace AJ Jr. p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res 2004;92:95-118.
5. Campbell RM, Anderson BD, Brooks NA, Brooks HB, Chan EM, De Dios A, et al. Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity. Mol Cancer Ther 2014;13: 364-74.
6. Pereira L, Igea A, Canovas B, Dolado I, Nebreda AR. Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK. EMBO Mol Med 2013; 5:1759-74.
7. Gupta J, del Barco Barrantes I, Igea A, Sakellariou S, Pateras IS, Gorgoulis VG, et al. Dual function of p38alpha MAPK in colon cancer: suppression of colitis-associated tumor initiation but requirement for cancer cell survival. Cancer Cell 2014;25:484-500.
8. Otsuka M, Kang YJ, Ren J, Jiang H, Wang Y, Omata M, et al. Distinct effects of p38alpha deletion inmyeloid lineage and gut epithelia in mouse models of inflammatory bowel disease. Gastroenterology 2010;138:1255-65, 65 e1-9.
9. Chiacchiera F, Matrone A, Ferrari E, Ingravallo G, Lo Sasso G, Murzilli S, et al. p38alpha blockade inhibits colorectal cancer growth in vivo by inducing a switch from HIF1alpha- to FoxO-dependent transcription. Cell Death Differ 2009;16:1203-14.
10. Ventura JJ, Tenbaum S, Perdiguero E, Huth M, Guerra C, Barbacid M, et al. p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet 2007;39:750-8.
11. Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L, et al. p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet 2007;39:741-9.
12. Sakurai T, He G, Matsuzawa A, Yu GY, Maeda S, Hardiman G, et al. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 2008;14:156-65.
13. Feng Y, Wen J, Chang CC. p38 Mitogen-activated protein kinase and hematologic malignancies. Arch Pathol Lab Med 2009;133:1850-6.
14. Navas TA, Mohindru M, Estes M, Ma JY, Sokol L, Pahanish P, et al. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood 2006;108:4170-7.
15. Sato A, Okada M, Shibuya K, Watanabe E, Seino S, Narita Y, et al. Pivotal role for ROS activation of p38 MAPK in the control of differentiation and tumor-initiating capacity of glioma-initiating cells. Stem Cell Res 2014; 12:119-31.
16. Gil-Araujo B, Toledo Lobo MV, Gutierrez-Salmeron M, Gutierrez-Pitalua J, Ropero S, Angulo JC, et al. Dual specificity phosphatase 1 expression inversely correlates with NF-kappaB activity and expression in prostate cancer and promotes apoptosis through a p38 MAPK dependent mechanism. Mol Oncol 2014;8:27-38.
17. Massague J. TGFbeta signalling in context. Nat Rev Mol Cell Biol 2012; 13:616-30.
18. Urosevic J, Garcia-Albeniz X, Planet E, Real S, Cespedes MV, Guiu M, et al. Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH. Nat Cell Biol 2014;16:685-94.
19. Yao Y, Fang ZP, Chen H, Yue L, Min DL, Tang LN, et al. HGFK1 inhibits bone metastasis in breast cancer through the TAK1/p38 MAPK signaling pathway. Cancer Gene Ther 2012;19:601-8.
20. del Barco Barrantes I, Nebreda AR. Roles of p38 MAPKs in invasion and metastasis. Biochem Soc Trans 2012;40:79-84.
21. Wu X, Zhang W, Font-Burgada J, Palmer T, Hamil AS, Biswas SK, et al. Ubiquitin-conjugating enzyme Ubc13 controls breast cancer metastasis through a TAK1-p38 MAP kinase cascade. Proc Natl Acad Sci U S A 2014;111:13870-5.
22. Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer 2014;14:611-22.
23. Bragado P, Estrada Y, Parikh F, Krause S, Capobianco C, Farina HG, et al. TGFbeta2 dictates disseminated tumour cell fate in target organs through TGFbeta-RIII and p38alpha/beta signalling. Nat Cell Biol 2013;15:1351-61.
24. Porras A, Guerrero C. Role of p38a in apoptosis: implication in cancer development and theraphy. Atlas Genet Cytogenet Oncol Haematol 2011; 15:316-26.
25. de la Cruz-Morcillo MA, Garcia-Cano J, Arias-Gonzalez L, Garcia-Gil E, Artacho-Cordon F, Rios-Arrabal S, et al. Abrogation of the p38 MAPK alpha signaling pathway does not promote radioresistance but its activity is required for 5-Fluorouracil-associated radiosensitivity. Cancer Lett 2013; 335:66-74.
26. Parmar S, Katsoulidis E, Verma A, Li Y, Sassano A, Lal L, et al. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. J Biol Chem 2004;279:25345-52.
27. Grossi V, Peserico A, Tezil T, Simone C. p38alpha MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance. World J Gastroenterol 2014;20:9744-58.
28. Paillas S, Boissiere F, Bibeau F, Denouel A, Mollevi C, Causse A, et al. Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma. Cancer Res 2011;71:1041-9.
29. Giafis N, Katsoulidis E, Sassano A, Tallman MS, Higgins LS, Nebreda AR, et al. Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer Res 2006;66:6763-71.
30. Rudalska R, Dauch D, Longerich T, McJunkin K, Wuestefeld T, Kang TW, et al. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat Med 2014;20:1138-46.
31. Desideri E, Vegliante R, Cardaci S, Nepravishta R, Paci M, Ciriolo MR. MAPK14/p38alpha-dependent modulation of glucose metabolism affects ROS levels and autophagy during starvation. Autophagy 2014;10: 1652-65.
32. Thornton TM, Pedraza-Alva G, Deng B, Wood CD, Aronshtam A, Clements JL, et al. Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. Science 2008;320:667-70.
33. del Barco Barrantes I, Coya JM, Maina F, Arthur JS, Nebreda AR. Genetic analysis of specific and redundant roles for p38alpha and p38beta MAPKs during mouse development. Proc Natl Acad Sci U S A 2011; 108:12764-9.
34. Newby LK, Marber MS, Melloni C, Sarov-Blat L, Aberle LH, Aylward PE, et al. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. Lancet 2014;384: 1187-95.
35. Morandell S, Reinhardt HC, Cannell IG, Kim JS, Ruf DM, Mitra T, et al. A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. Cell Rep 2013;5:868-77.